WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical ...
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on Disc Medicine (IRON – Research Report), with a price target of $85.00. The company’s shares closed yesterday at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback